Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER Positive, HER2 Negative Breast Cancer Neoplasms”

365 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 365 results

Early research (Phase 1)Ended earlyNCT03816839
What this trial is testing

Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

Who this might be right for
Breast Cancer
Sanofi 10
Large-scale testing (Phase 3)Study completedNCT01626222
What this trial is testing

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 301
Testing effectiveness (Phase 2)Ended earlyNCT04738292
What this trial is testing

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

Who this might be right for
ER-positive Breast CancerHER2-negative Breast CancerMetastatic Cancer
University of Wisconsin, Madison 11
Large-scale testing (Phase 3)Looking for participantsNCT02535221
What this trial is testing

Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer

Who this might be right for
Breast Cancer
Peking University 234
Testing effectiveness (Phase 2)Study completedNCT02049957
What this trial is testing

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Calithera Biosciences, Inc 118
Testing effectiveness (Phase 2)UnknownNCT00687648
What this trial is testing

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
National Cancer Centre, Singapore 70
Testing effectiveness (Phase 2)Study completedNCT05101564
What this trial is testing

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerER Positive Breast Cancer
Jennifer Lee Caswell-Jin 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT04759248
What this trial is testing

Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 55
Not applicableStudy completedNCT02773004
What this trial is testing

Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer

Who this might be right for
Breast Cancer
UNICANCER 203
Large-scale testing (Phase 3)Active Not RecruitingNCT00070564
What this trial is testing

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network 3,294
Testing effectiveness (Phase 2)UnknownNCT04247633
What this trial is testing

High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)

Who this might be right for
Breast Cancer
Samsung Medical Center 578
Early research (Phase 1)Study completedNCT04176757
What this trial is testing

ZN-c5 in Participants With Breast Cancer

Who this might be right for
Breast Cancer
Zeno Alpha Inc. 35
Testing effectiveness (Phase 2)Ended earlyNCT05618613
What this trial is testing

Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Context Therapeutics Inc. 4
Large-scale testing (Phase 3)Active Not RecruitingNCT04964934
What this trial is testing

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 315
Large-scale testing (Phase 3)Study completedNCT00630032
What this trial is testing

Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer

Who this might be right for
Breast Cancer
UNICANCER 762
Testing effectiveness (Phase 2)Study completedNCT03250676
What this trial is testing

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Who this might be right for
Breast NeoplasmsBreast CancerEstrogen-receptor Positive Breast Cancer+5 more
Eisai Inc. 151
Testing effectiveness (Phase 2)WithdrawnNCT04901299
What this trial is testing

Fulvestrant + Neratinib In Breast Cancer

Who this might be right for
Stage IV (Metastatic) Breast CancerMetastatic Breast CancerER Positive Breast Cancer+3 more
Massachusetts General Hospital
Testing effectiveness (Phase 2)WithdrawnNCT06938711
What this trial is testing

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Context Therapeutics Inc.
Not applicableLooking for participantsNCT06867484
What this trial is testing

Breast Re-irradiation After Second Ipsilateral Lumpectomy

Who this might be right for
Breast CancerCancerCancer of the Breast+3 more
Youssef Zeidan 114
Testing effectiveness (Phase 2)Ended earlyNCT03584009
What this trial is testing

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

Who this might be right for
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 103
Load More Results